| COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials A Desai, JF Gainor, A Hegde, AM Schram, G Curigliano, S Pal, SV Liu, ... Nature reviews Clinical oncology 18 (5), 313-319, 2021 | 151 | 2021 |
| Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials R Groisberg, DS Hong, A Behrang, K Hess, F Janku, S Piha-Paul, ... Journal for immunotherapy of cancer 5, 1-8, 2017 | 140 | 2017 |
| Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers M Palmeri, J Mehnert, AW Silk, SK Jabbour, S Ganesan, P Popli, ... ESMO open 7 (1), 100336, 2022 | 124 | 2022 |
| Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas R Groisberg, DS Hong, V Holla, F Janku, S Piha-Paul, V Ravi, R Benjamin, ... Oncotarget 8 (24), 39254, 2017 | 73 | 2017 |
| Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer SJ Wang, K Khullar, S Kim, N Yegya-Raman, J Malhotra, R Groisberg, ... Journal for Immunotherapy of Cancer 8 (2), 2020 | 40 | 2020 |
| The role of next-generation sequencing in sarcomas: Evolution from light microscope to molecular microscope R Groisberg, J Roszik, A Conley, SR Patel, V Subbiah Current oncology reports 19, 1-8, 2017 | 39 | 2017 |
| Clinical next-generation sequencing for precision oncology in rare cancers R Groisberg, DS Hong, J Roszik, F Janku, AM Tsimberidou, M Javle, ... Molecular cancer therapeutics 17 (7), 1595-1601, 2018 | 38 | 2018 |
| BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant … JM Mehnert, TC Mitchell, AC Huang, TS Aleman, BJ Kim, LM Schuchter, ... Clinical Cancer Research 28 (6), 1098-1106, 2022 | 35 | 2022 |
| Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials H Maymani, K Hess, R Groisberg, DS Hong, A Naing, S Piha-Paul, ... Lung Cancer 120, 137-141, 2018 | 32 | 2018 |
| Precision oncology in sarcomas: divide and conquer R Carmagnani Pestana, R Groisberg, J Roszik, V Subbiah JCO Precision Oncology 3, 1-16, 2019 | 30 | 2019 |
| Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma G Rabinowits Journal of Clinical Oncology 39 (15_suppl), 2021 | 27 | 2021 |
| Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors V Dembla, R Groisberg, K Hess, S Fu, J Wheler, DS Hong, F Janku, ... Scientific reports 7 (1), 15963, 2017 | 23 | 2017 |
| Genomics, morphoproteomics, and treatment patterns of patients with alveolar soft part sarcoma and response to multiple experimental therapies R Groisberg, J Roszik, AP Conley, AJ Lazar, DE Portal, DS Hong, A Naing, ... Molecular cancer therapeutics 19 (5), 1165-1172, 2020 | 22 | 2020 |
| Unique aberrations in intimal sarcoma identified by next-generation sequencing as potential therapy targets J Roszik, A Khan, AP Conley, JA Livingston, R Groisberg, V Ravi, ... Cancers 11 (9), 1283, 2019 | 22 | 2019 |
| Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated … V Subbiah, S Sen, KR Hess, F Janku, DS Hong, S Khatua, DD Karp, ... JCO Precision Oncology 2, 1-12, 2018 | 18 | 2018 |
| Evaluation of a gene expression profiling assay in primary cutaneous melanoma AW Kangas-Dick, A Greenbaum, V Gall, R Groisberg, J Mehnert, C Chen, ... Annals of Surgical Oncology 28, 4582-4589, 2021 | 16 | 2021 |
| Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes P Markowitz, M Patel, R Groisberg, J Aisner, SK Jabbour, S De, ... Cancer treatment and research communications 25, 100232, 2020 | 14 | 2020 |
| EZH2 inhibition for epithelioid sarcoma and follicular lymphoma R Groisberg, V Subbiah The lancet oncology 21 (11), 1388-1390, 2020 | 12 | 2020 |
| A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors AW Silk, B Saraiya, R Groisberg, N Chan, K Spencer, E Girda, W Shih, ... European Journal of Medical Research 27 (1), 107, 2022 | 10 | 2022 |
| Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study. Y Nakamura, N Mizuno, Y Sunakawa, EP Hamilton, H Hayashi, ST Kim, ... Journal of clinical oncology 41 (16_suppl), 4007-4007, 2023 | 9 | 2023 |
Vivek Subbiah, MDAssociate Professor, The University of Texas MD Anderson Cancer Centermdanderson.org üzerinde doğrulanmış e-posta adresine sahip
